NexImmune, Inc. logo

NexImmune, Inc.

NexImmune is an early-stage biopharma company, developing novel immuno-therapeutics for the treatment of various diseases utilizing its proprietary Artificial IMmune (AIM_) nanotechnology.

NexImmune obtained exclusive license to AIM_ technology from Johns Hopkins University, developed in the laboratory of Dr. Mathias Oelke and Dr. Jonathan Schneck. The technology is focused on creating synthetic white blood cells that help the bodys immune system recognize tumors and other harmful substances.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.neximmune.com
Founded2011
Disease Focus
Development Stage
STOCK CODENon Listed
Address
9119 Gaither Road, MD, 20877
Gaithersburg
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/neximmune-inc.” connections=”true” suffix=””]

NexImmunes Artificial IMmune (AIM_) nanotechnology platform replaces damaged, absent or inactive natural APCs with precisely engineered artificial Antigen Presenting Cells (aAPC) that direct a specific immune response. aAPC can be loaded with a defined assortment of tumor-associated antigens and co-stimulatory molecules.

In Feb 2017, NexImmune, was acquired by a consortium of big-name biotech veterans and investors with undisclose terms of the deal.

In July 2014, NexImmune secured $23 Mn in Series A financing co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital, along with significant participation from Piedmont Capital Partners.

In July 2014, NexImmune secured $3 Mn in financing led by New Enterprise Associates (NEA), Pfizer Venture Investments and Amgen Ventures. Also in July 2013, company received an SBIR grant of $290,000 from the NIH for the development of a human therapeutic based on AIM Technology.